472 related articles for article (PubMed ID: 29167877)
1. Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.
Javitt DC; Carter CS; Krystal JH; Kantrowitz JT; Girgis RR; Kegeles LS; Ragland JD; Maddock RJ; Lesh TA; Tanase C; Corlett PR; Rothman DL; Mason G; Qiu M; Robinson J; Potter WZ; Carlson M; Wall MM; Choo TH; Grinband J; Lieberman JA
JAMA Psychiatry; 2018 Jan; 75(1):11-19. PubMed ID: 29167877
[TBL] [Abstract][Full Text] [Related]
2. Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers.
Kantrowitz JT; Grinband J; Goff DC; Lahti AC; Marder SR; Kegeles LS; Girgis RR; Sobeih T; Wall MM; Choo TH; Green MF; Yang YS; Lee J; Horga G; Krystal JH; Potter WZ; Javitt DC; Lieberman JA
Neuropsychopharmacology; 2020 Oct; 45(11):1842-1850. PubMed ID: 32403118
[TBL] [Abstract][Full Text] [Related]
3. Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data.
Merritt K; McGuire PK; Egerton A; ; Aleman A; Block W; Bloemen OJN; Borgan F; Bustillo JR; Capizzano AA; Coughlin JM; De la Fuente-Sandoval C; Demjaha A; Dempster K; Do KQ; Du F; Falkai P; Galinska-Skok B; Gallinat J; Gasparovic C; Ginestet CE; Goto N; Graff-Guerrero A; Ho BC; Howes OD; Jauhar S; Jeon P; Kato T; Kaufmann CA; Kegeles LS; Keshavan M; Kim SY; Kunugi H; Lauriello J; Liemburg EJ; Mcilwain ME; Modinos G; Mouchlianitis ED; Nakamura J; Nenadic I; Öngür D; Ota M; Palaniyappan L; Pantelis C; Plitman E; Posporelis S; Purdon SE; Reichenbach JR; Renshaw PF; Russell BR; Sawa A; Schaefer M; Shungu DC; Smesny S; Stanley JA; Stone JM; Szulc A; Taylor R; Thakkar K; Théberge J; Tibbo PG; van Amelsvoort T; Walecki J; Williamson PC; Wood SJ; Xin L; Yamasue H
JAMA Psychiatry; 2021 Jun; 78(6):667-681. PubMed ID: 33881460
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study.
Taylor MJ; Tiangga ER; Mhuircheartaigh RN; Cowen PJ
J Psychopharmacol; 2012 May; 26(5):733-7. PubMed ID: 21616979
[TBL] [Abstract][Full Text] [Related]
5. Ketamine effects on brain function--simultaneous fMRI/EEG during a visual oddball task.
Musso F; Brinkmeyer J; Ecker D; London MK; Thieme G; Warbrick T; Wittsack HJ; Saleh A; Greb W; de Boer P; Winterer G
Neuroimage; 2011 Sep; 58(2):508-25. PubMed ID: 21723949
[TBL] [Abstract][Full Text] [Related]
6. The potential of
Egerton A
Psychopharmacology (Berl); 2021 May; 238(5):1241-1254. PubMed ID: 31486875
[TBL] [Abstract][Full Text] [Related]
7. Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA).
Egerton A; Murphy A; Donocik J; Anton A; Barker GJ; Collier T; Deakin B; Drake R; Eliasson E; Emsley R; Gregory CJ; Griffiths K; Kapur S; Kassoumeri L; Knight L; Lambe EJB; Lawrie SM; Lees J; Lewis S; Lythgoe DJ; Matthews J; McGuire P; McNamee L; Semple S; Shaw AD; Singh KD; Stockton-Powdrell C; Talbot PS; Veronese M; Wagner E; Walters JTR; Williams SR; MacCabe JH; Howes OD
Schizophr Bull; 2021 Mar; 47(2):505-516. PubMed ID: 32910150
[TBL] [Abstract][Full Text] [Related]
8. 7T
Evans JW; Lally N; An L; Li N; Nugent AC; Banerjee D; Snider SL; Shen J; Roiser JP; Zarate CA
Neuropsychopharmacology; 2018 Aug; 43(9):1908-1914. PubMed ID: 29748628
[TBL] [Abstract][Full Text] [Related]
9. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial.
Voineskos AN; Mulsant BH; Dickie EW; Neufeld NH; Rothschild AJ; Whyte EM; Meyers BS; Alexopoulos GS; Hoptman MJ; Lerch JP; Flint AJ
JAMA Psychiatry; 2020 Jul; 77(7):674-683. PubMed ID: 32101271
[TBL] [Abstract][Full Text] [Related]
10. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.
Stone JM
Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330
[TBL] [Abstract][Full Text] [Related]
11. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Deakin JF; Lees J; McKie S; Hallak JE; Williams SR; Dursun SM
Arch Gen Psychiatry; 2008 Feb; 65(2):154-64. PubMed ID: 18250253
[TBL] [Abstract][Full Text] [Related]
12. Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex.
Fan L; Liang L; Wang Y; Ma X; Yuan L; Ouyang L; He Y; Li Z; Li C; Chen X; Palaniyappan L
Neuropsychopharmacology; 2024 Apr; 49(5):845-853. PubMed ID: 37752221
[TBL] [Abstract][Full Text] [Related]
13. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol modulation of hippocampal glutamate in early psychosis.
O'Neill A; Annibale L; Blest-Hopley G; Wilson R; Giampietro V; Bhattacharyya S
J Psychopharmacol; 2021 Jul; 35(7):814-822. PubMed ID: 33860709
[TBL] [Abstract][Full Text] [Related]
15. Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents.
Doyle OM; De Simoni S; Schwarz AJ; Brittain C; O'Daly OG; Williams SC; Mehta MA
J Pharmacol Exp Ther; 2013 Apr; 345(1):151-60. PubMed ID: 23370794
[TBL] [Abstract][Full Text] [Related]
16. Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration.
Egerton A; Griffiths K; Casetta C; Deakin B; Drake R; Howes OD; Kassoumeri L; Khan S; Lankshear S; Lees J; Lewis S; Mikulskaya E; Millgate E; Oloyede E; Pollard R; Rich N; Segev A; Sendt KV; MacCabe JH
Neuropsychopharmacology; 2023 Feb; 48(3):567-575. PubMed ID: 36456813
[TBL] [Abstract][Full Text] [Related]
17. Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects.
Mehta MA; Schmechtig A; Kotoula V; McColm J; Jackson K; Brittain C; Tauscher-Wisniewski S; Kinon BJ; Morrison PD; Pollak T; Mant T; Williams SCR; Schwarz AJ
Psychopharmacology (Berl); 2018 Jul; 235(7):1875-1886. PubMed ID: 29564482
[TBL] [Abstract][Full Text] [Related]
18. Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
Merritt K; Egerton A; Kempton MJ; Taylor MJ; McGuire PK
JAMA Psychiatry; 2016 Jul; 73(7):665-74. PubMed ID: 27304221
[TBL] [Abstract][Full Text] [Related]
19. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial.
Barch DM; Marder SR; Harms MP; Jarskog LF; Buchanan RW; Cronenwett W; Chen LS; Weiss M; Maguire RP; Pezous N; Feuerbach D; Lopez-Lopez C; Johns DR; Behrje RB; Gomez-Mancilla B
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():66-75. PubMed ID: 27371157
[TBL] [Abstract][Full Text] [Related]
20. Ketamine modulates hippocampal neurochemistry and functional connectivity: a combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers.
Kraguljac NV; Frölich MA; Tran S; White DM; Nichols N; Barton-McArdle A; Reid MA; Bolding MS; Lahti AC
Mol Psychiatry; 2017 Apr; 22(4):562-569. PubMed ID: 27480494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
